News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MGI Pharma Inc. (MOGN) And SuperGen, Inc. (SUPG): Approvable Letter Received From The FDA For Dacogen(TM) (Decitabine) Injection For The Treatment Of MDS; FDA Asks For More Info


10/19/2005 5:09:12 PM

MINNEAPOLIS & DUBLIN, Calif.--(BUSINESS WIRE)--Sept. 1, 2005--MGI PHARMA, INC. (Nasdaq:MOGN) and SuperGen, Inc. (Nasdaq:SUPG) today announced they have received an approvable letter from the U.S. Food and Drug Administration (FDA) for Dacogen(TM) (decitabine) injection for the treatment of myelodysplastic syndromes (MDS). The letter provides that Dacogen injection is approvable pending the FDA's review of a requested analysis of the transfusion requirements of patients enrolled in the completed phase 3 trial, submission of certain other information, and completion of labeling discussions.

Read at Forbes
Read at AP
Read at BioSpace.com

comments powered by Disqus
Forbes
AP
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES